MARKET

CYCCP

CYCCP

Cyclacel Phar Pr
NASDAQ
9.17
0.00
0.00%
Closed 16:00 11/29 EST
OPEN
9.17
PREV CLOSE
9.17
HIGH
9.17
LOW
9.17
VOLUME
30
TURNOVER
0
52 WEEK HIGH
22.58
52 WEEK LOW
5.25
MARKET CAP
3.07M
P/E (TTM)
-4.6171
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CYCCP last week (1120-1124)?
Weekly Report · 3d ago
Weekly Report: what happened at CYCCP last week (1113-1117)?
Weekly Report · 11/20 09:42
Cyclacel Phar Pr: Current report
Press release · 11/16 00:38
Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock Shares Cross 6.5% Yield Mark
NASDAQ · 11/15 22:42
Cyclacel Phar Pr: Current report
Press release · 11/14 02:41
Weekly Report: what happened at CYCCP last week (1106-1110)?
Weekly Report · 11/13 09:39
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers intelligent bio solutions shares increased by 156.6% to $0.58 during thursday's regular session. Tempest therapeutics (nasdaq:tpst) shares rose 33.32% after the company's, q1 earnings came out yesterday. Oncocyte stock rose 20.67% and lantern pharma stock moved upwards by 28.12% during the session.
Benzinga · 11/09 17:31
Cyclacel Phar Pr: Current report
Press release · 11/08 03:11
More
About CYCCP
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in solid tumors and hematological malignancies. The Company's Mitosis Regulation program includes Plogosertib, which is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor. Plogosertib has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and impressive efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in acute leukemias and solid tumors.

Webull offers Cyclacel Pharmaceuticals Inc stock information, including NASDAQ: CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYCCP stock methods without spending real money on the virtual paper trading platform.